House Oversight Committee Interviews on Biden’s Health

Jonathan Turley, a law professor at George Washington University, provided insights on why the House Oversight Committee interviewed Biden administration officials regarding former President Joe Biden’s cognitive decline during his time in office.

The committee began reaching out to senior Biden officials in May. This was partly in response to a book set to be released in spring 2025, which details Biden’s health issues and cognitive decline. The committee’s aim, Turley noted, was to gather consistent testimony from those close to Biden.

“What they’re trying to do is to ensure that witnesses give their testimony under oath, as they dig into this matter,” Turley shared during a discussion with Bill Hemmer on American Report. He added, “We all observed this during the campaign when his staff often kept him out of the limelight and avoided interactions with reporters. There was disbelief regarding his ability to engage in conversations with the press, which only seemed to worsen over time.”

Turley elaborated, stating, “While the Constitution permits a president to take office, the process can be quite complex. It also doesn’t take into account the potentially harmful motivations of the staff. As long as the president is breathing, he retains his powers, which is the underlying concern. So, the committee is working hard to secure this testimony and explore the issue more deeply, as it seems they plan to have this president primarily read from a prompter.”

Questions concerning Biden’s use of an Autopen device arose after Trump claimed in March that he could use a device to replicate a saved signature for official documents during Biden’s administration. This was connected to ongoing discussions about the January 6th Capitol riots, suggesting that the legitimacy of the events could be questioned due to the use of such devices.

Moreover, concerns over Biden’s health intensified after an announcement on May 18 that he had been diagnosed with an aggressive stage of prostate cancer that had metastasized to the bone. Typically, prostate cancer at this stage is classified as 4B, with a five-year survival rate of around 37%, according to the Mayo Clinic.